Research programme: cancer immunotherapies - BeneVir Biopharm

Drug Profile

Research programme: cancer immunotherapies - BeneVir Biopharm

Alternative Names: Stealth-1H

Latest Information Update: 03 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BeneVir Biopharm
  • Class Oncolytic viruses
  • Mechanism of Action Antigen-presenting-cell-modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours
  • Research Cancer

Most Recent Events

  • 25 Apr 2017 BeneVir Biopharma recevies patent protection for Stealth 1H in USA
  • 19 Nov 2014 Early research in Cancer in USA (unspecified route)
  • 19 Nov 2014 Preclinical development for Solid tumours (Metastatic disease) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top